Tanvex Biopharma Stock Current Liabilities
| 6541 Stock | TWD 70.30 2.20 3.23% |
Tanvex BioPharma fundamentals help investors to digest information that contributes to Tanvex BioPharma's financial success or failures. It also enables traders to predict the movement of Tanvex Stock. The fundamental analysis module provides a way to measure Tanvex BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tanvex BioPharma stock.
Tanvex |
Tanvex BioPharma Company Current Liabilities Analysis
Tanvex BioPharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Tanvex BioPharma has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all Taiwan stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Tanvex Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (76.42) % | |||
| Current Valuation | 14.19 B | |||
| Shares Outstanding | 352.74 M | |||
| Shares Owned By Insiders | 53.74 % | |||
| Shares Owned By Institutions | 4.30 % | |||
| Price To Book | 7.12 X | |||
| Price To Sales | 681.78 X | |||
| Revenue | 5.41 M | |||
| Gross Profit | 3.55 M | |||
| EBITDA | (1.25 B) | |||
| Net Income | (1.54 B) | |||
| Cash And Equivalents | 1.65 B | |||
| Cash Per Share | 5.29 X | |||
| Debt To Equity | 0.67 % | |||
| Current Ratio | 7.89 X | |||
| Book Value Per Share | 5.35 X | |||
| Cash Flow From Operations | (1.39 B) | |||
| Earnings Per Share | (4.35) X | |||
| Target Price | 52.4 | |||
| Number Of Employees | 23 | |||
| Beta | 0.67 | |||
| Market Capitalization | 17.11 B | |||
| Total Asset | 4.71 B | |||
| Net Asset | 4.71 B |
About Tanvex BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tanvex BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tanvex BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tanvex BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.